Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 0.34 |
| ▸ | WDR5 | P61964 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | FNTA | P49354 | 10/20 | 0.33 |
| ▸ | FNTB | P49356 | 10/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18282111 | 0.90 | KDM4E (0.38) | KMT2A | |
| SCHEMBL18282153 | 0.89 | MAPT (0.33) | MYCWDR5KMT2A | |
| SCHEMBL18282103 | 0.88 | RIPK2 (0.35) | FNTAFNTBKMT2ALMNA | |
| SCHEMBL18282282 | 0.88 | S1PR1 (0.34) | MYCWDR5KMT2ALMNA | |
| SCHEMBL18282030 | 0.86 | FNTA (0.36) | FNTAFNTBKMT2A | |
| SCHEMBL18282209 | 0.85 | MYC (0.39) | MYCWDR5FNTAFNTBKMT2A | |
| SCHEMBL18282126 | 0.84 | SLC6A3 (0.36) | KMT2ALMNA | |
| SCHEMBL18282158 | 0.82 | ALDH1A1 (0.32) | MYCWDR5LMNA | |
| SCHEMBL18282243 | 0.82 | MAPK14 (0.36) | FNTAFNTBKMT2ALMNA | |
| SCHEMBL18282078 | 0.82 | ALDH1A1 (0.37) | MYCWDR5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2024-11-26 | — | — | US | disclosed |
| US-11602526-B2 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto | BANTAM PHARMACEUTICAL, LLC (US) | 2023-03-14 | — | — | US | disclosed |
| US-20200261424-A1 | Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto | BANTAM PHARMACEUTICAL, LLC | 2020-08-20 | — | — | US | disclosed |
| US-20200069656-A1 | Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases | BANTAM PHARMACEUTICAL, LLC | 2020-03-05 | — | — | US | disclosed |
| CN-110769823-A | Methods of using substituted pyrazole and pyrrole compounds and treating hyperproliferative diseases | 班塔姆制药有限责任公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-3548024-A2 | METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bantam Pharmaceutical, LLC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180311218-A1 | Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto | EGENIX, INC. | 2018-11-01 | — | — | US | disclosed |
| WO-2018102452-A2 | METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES | BANTAM PHARMACEUTICAL, LLC (US) | 2018-06-07 | — | — | WO | disclosed |
| EP-3303332-A1 | SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO | Bantam Pharmaceutical, LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016196644-A1 | SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO | BANTAM PHARMACEUTICAL, LLC (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261424-A1 | Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto | EIF4A1, EIF4A3, EIF4B | MYC 453/4885WDR5 1327/4885XDH 972/4885 |
| US-20180311218-A1 | Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto | EIF4A3, EIF4A1, EIF4B | MYC 1215/4885WDR5 1150/4885XDH 1285/4885 |
| US-20200069656-A1 | Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases | KRAS, TP53, CCNA1 | MYC 81/4885WDR5 3041/4885XDH 215/4885 |
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | KRAS, TP53, CCNA1 | MYC 81/4885WDR5 3041/4885XDH 215/4885 |
| US-11602526-B2 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto | EIF4A1, EIF4A3, EIF4B | MYC 453/4885WDR5 1327/4885XDH 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.